Cardiol Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
David Elsley
Chief executive officer
CA$748.1k
Total compensation
| CEO salary percentage | 70.2% |
| CEO tenure | 8yrs |
| CEO ownership | 1.5% |
| Management average tenure | 4.1yrs |
| Board average tenure | 3yrs |
Recent management updates
Recent updates
We're Not Very Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate
Sep 12
Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Deliver On Growth Plans?
May 01Will Cardiol Therapeutics (TSE:CRDL) Spend Its Cash Wisely?
Jan 06Is Cardiol Therapeutics (TSE:CRDL) In A Good Position To Invest In Growth?
Sep 13We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully
May 24We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth
Jan 20We Think Cardiol Therapeutics (TSE:CRDL) Can Afford To Drive Business Growth
Aug 10We're Not Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn
Apr 17Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation
Dec 09We Think Cardiol Therapeutics (TSE:CRDL) Needs To Drive Business Growth Carefully
Aug 19Here's Why We're Not Too Worried About Cardiol Therapeutics' (TSE:CRDL) Cash Burn Situation
Apr 18Companies Like Cardiol Therapeutics (TSE:CRDL) Are In A Position To Invest In Growth
Jan 03CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -CA$36m |
| Jun 30 2024 | n/a | n/a | -CA$29m |
| Mar 31 2024 | n/a | n/a | -CA$30m |
| Dec 31 2023 | CA$748k | CA$525k | -CA$28m |
| Sep 30 2023 | n/a | n/a | -CA$28m |
| Jun 30 2023 | n/a | n/a | -CA$30m |
| Mar 31 2023 | n/a | n/a | -CA$29m |
| Dec 31 2022 | CA$654k | CA$525k | -CA$31m |
| Sep 30 2022 | n/a | n/a | -CA$30m |
| Jun 30 2022 | n/a | n/a | -CA$32m |
| Mar 31 2022 | n/a | n/a | -CA$32m |
| Dec 31 2021 | CA$1m | CA$455k | -CA$32m |
| Sep 30 2021 | n/a | n/a | -CA$35m |
| Jun 30 2021 | n/a | n/a | -CA$30m |
| Mar 31 2021 | n/a | n/a | -CA$27m |
| Dec 31 2020 | CA$517k | CA$450k | -CA$21m |
| Sep 30 2020 | n/a | n/a | -CA$14m |
| Jun 30 2020 | n/a | n/a | -CA$13m |
| Mar 31 2020 | n/a | n/a | -CA$13m |
| Dec 31 2019 | CA$450k | CA$450k | -CA$14m |
| Sep 30 2019 | n/a | n/a | -CA$20m |
| Jun 30 2019 | n/a | n/a | -CA$21m |
| Mar 31 2019 | n/a | n/a | -CA$19m |
| Dec 31 2018 | CA$713k | CA$363k | -CA$16m |
Compensation vs Market: David's total compensation ($USD518.67K) is above average for companies of similar size in the Canadian market ($USD166.88K).
Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.
CEO
David Elsley
8yrs
Tenure
CA$748,100
Compensation
Mr. David G. Elsley, MBA, has been the President, Chief Executive Officer and Director of Cardiol Therapeutics Inc since January 19, 2017. Mr. Elsley is a business leader with a proven track record of deve...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8yrs | CA$748.10k | 1.53% CA$ 2.3m | |
| CFO, Corporate Secretary & Director | 6.4yrs | CA$294.80k | 0.17% CA$ 251.4k | |
| Chief Operating Officer | 4.1yrs | CA$515.90k | 0.049% CA$ 74.0k | |
| Chief Medical Officer & Head of Research & Development | 3.8yrs | CA$746.56k | 0.57% CA$ 863.2k | |
| Investor Relations | no data | no data | no data | |
| Vice President of Corporate Development | less than a year | no data | no data |
4.1yrs
Average Tenure
Experienced Management: CRDL's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8yrs | CA$748.10k | 1.53% CA$ 2.3m | |
| CFO, Corporate Secretary & Director | 2.7yrs | CA$294.80k | 0.17% CA$ 251.4k | |
| Independent Director | 5.1yrs | CA$60.00k | 0.17% CA$ 263.6k | |
| Independent Director | 2.8yrs | CA$76.92k | 0.12% CA$ 185.0k | |
| Independent Director | 7.1yrs | CA$58.00k | 0.62% CA$ 936.2k | |
| Independent Director | 3.3yrs | CA$71.52k | 1.04% CA$ 1.6m | |
| Member of Scientific Advisory Board | 3yrs | no data | no data | |
| Member of Scientific Advisory Board | 3yrs | no data | no data | |
| Independent Director | 2.7yrs | CA$82.32k | 0.15% CA$ 222.0k | |
| Independent Chairman | 6.4yrs | CA$112.68k | 0.32% CA$ 479.7k | |
| Member of Scientific Advisory Board | 3yrs | no data | no data |
3.0yrs
Average Tenure
56yo
Average Age
Experienced Board: CRDL's board of directors are considered experienced (3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 22:32 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cardiol Therapeutics Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Nash | Canaccord Genuity |
| Charles Duncan | Cantor Fitzgerald & Co. |
| Christian Orquera | First Berlin Equity Research GmbH |